Ocugen, Inc. (OCGN)
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Shankar Musunuri M.B.A., Ph.D.
|
Co-Founder, CEO & Chairman | 1.26M | -- | 1964 |
|
Dr. Arun Upadhyay Ph.D.
|
Chief Scientific Officer and Head of Research & Development | 703.75k | -- | 1982 |
|
Ms. Rita Johnson-Greene M.B.A.
|
CFO & Principal Accounting Officer | -- | -- | 1977 |
|
Mr. Paul Staid
|
Executive Vice President of Operations | -- | -- | -- |
|
John Kouch J.D.
|
General Counsel | -- | -- | -- |
|
Mr. Chris Clark
|
VP of Corporate Communications | -- | -- | -- |
|
Ms. Kristen Craft
|
Head of People & Culture | -- | -- | -- |
|
Dr. Vijay Tammara Ph.D.
|
Chief Development Officer | 490.92k | 575.63k | 1960 |
|
Dr. Mohamed Genead M.D., M.Sc.
|
Chief Medical Officer | -- | -- | -- |
|
Ms. Jyothy Pillai M.S.
|
VP & Head of Regulatory & Quality | -- | -- | -- |
Ocugen, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 116
Description
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Corporate Governance
Upcoming Events
November 4, 2026 at 1:30 PM UTC
Ocugen, Inc. Earnings Date
